<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39411224</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Estimated Deaths Averted in Adults by COVID-19 Vaccination in Select Latin American and Caribbean Countries.</ArticleTitle><Pagination><StartPage>ofae528</StartPage><MedlinePgn>ofae528</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae528</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae528</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on global health, with millions of lives lost worldwide. Vaccination has emerged as a crucial strategy in mitigating the impact of the disease. This study aims to estimate the number of deaths averted through vaccination in Latin America and the Caribbean region (LAC) during the first year and a half of vaccination rollout (January 2021-May 2022).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Publicly available data on COVID-19 deaths and vaccination rates were used to estimate the total number of deaths averted via vaccination in LAC. Using estimates for number of deaths, number of vaccinated, and vaccine effectiveness, a counterfactual estimated number of deaths observed without vaccination was calculated. Vaccine effectiveness estimates were obtained from published studies. The analysis focused on 17 countries in LAC and considered adults aged 18 years and older.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After accounting for underreporting, the analysis estimated that &gt;1.49 million deaths were caused by COVID-19 in the selected countries during the study period. Without vaccination, the model estimated that between 2.10 and 4.11 million COVID-19 deaths would have occurred. Consequently, vaccination efforts resulted in ∼610 000 to 2.61 million deaths averted.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study represents the first large-scale, multicenter estimate of population-level vaccine impact on COVID-19 mortality in LAC. The findings underscore the substantial impact of timely and widespread vaccination in averting COVID-19 deaths. These results provide crucial support for vaccination programs aimed at combating epidemic infectious diseases in the region and future pandemics.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savinkina</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5257-866X</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberger</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0003-1178-8086</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toscano</LastName><ForeName>Cristiana M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-9453-2643</Identifier><AffiliationInfo><Affiliation>Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, GO, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Oliveira</LastName><ForeName>Lucia H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Independent Consultant, working at Comprehensive Immunization Program, Pan-American Health Organization (PAHO) when the project was conceived.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Caribbean</Keyword><Keyword MajorTopicYN="N">Latin America</Keyword><Keyword MajorTopicYN="N">mathematical modeling</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. At time of project conception, Lucia H. De Oliveira was a staff member of the Pan American Health Organization. This author is responsible for the views expressed in this publication, and they do not necessarily represent the decisions or policies of the Pan American Health Organization. All other authors: no reported conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39411224</ArticleId><ArticleId IdType="pmc">PMC11474601</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae528</ArticleId><ArticleId IdType="pii">ofae528</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization . WHO coronavirus (COVID-19) dashboard. 2022. Available at: https://covid19.who.int/data. Accessed March 9, 2023.</Citation></Reference><Reference><Citation>
Pan-American Health Organization . Biweekly COVID-19 epidemiological update—region of the Americas. 2023. Available at: https://www.paho.org/en/documents/paho-biweekly-covid-19-epidemiologicalupdate-31st-may-2023. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>
World Health Organization . Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. 2021. Available at: https://www.who.int/teams/regulation-prequalification/eul/covid-194. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>
World Health Organization . Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. 2023. Available at: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_29May2023.pdf. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>
Pan-American Health Organization . Pharmacovigiliance for COVID-19 vaccines. 2022. Available at: https://covid-19pharmacovigilance.paho.org/. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>
Pan-American Health Organization . COVID-19 vaccination in the Americas dashboard. 2023. Available at: https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>Steele  MK, Couture  A, Reed  C, et al.  Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open  2022; 5:e2220385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260489</ArticleId><ArticleId IdType="pubmed">35793085</ArticleId></ArticleIdList></Reference><Reference><Citation>Savinkina  A, Bilinski  A, Fitzpatrick  M, et al.  Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open  2022; 12:e061752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9471205</ArticleId><ArticleId IdType="pubmed">36100306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu  E, Ritchie  H, Ortiz-Ospina  E, et al.  A global database of COVID-19 vaccinations. Nat Hum Behav  2021; 5:947–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">33972767</ArticleId></ArticleIdList></Reference><Reference><Citation>Riffe  T, Acosta  E. Data resource profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths. Int J Epidemiol  2021; 50:390–f.</Citation></Reference><Reference><Citation>Rizzi  S, Gampe  J, Eilers  PH. Efficient estimation of smooth distributions from coarsely grouped data. Am J Epidemiol  2015; 182:138–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493979</ArticleId><ArticleId IdType="pubmed">26081676</ArticleId></ArticleIdList></Reference><Reference><Citation>Msemburi  W, Karlinsky  A, Knutson  V, Aleshin-Guendel  S, Chatterji  S, Wakefield  J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature  2023; 613:130–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pan-American Health Organization . COVID-19 vaccination in the Americas. 2022. Available at: https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp. Accessed August 8, 2023.</Citation></Reference><Reference><Citation>Monteiro  HS, Lima Neto  AS, Kahn  R, et al.  Impact of CoronaVac on COVID-19 outcomes of elderly adults in a large and socially unequal Brazilian city: a target trial emulation study. Vaccine  2023; 41:5742–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">37573202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchings  MDT, Ranzani  OT, Dorion  M, et al.  Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. Nat Commun  2021; 12:6220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553924</ArticleId><ArticleId IdType="pubmed">34711813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermingham  C, Morgan  J, Ayoubkhani  D, et al.  Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study. Am J Epidemiol  2022; 192:267–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494386</ArticleId><ArticleId IdType="pubmed">36065824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn  R, Janusz  CB, Castro  MC, et al.  The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case-control study. Lancet Reg Health Am  2023; 20:100474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10049854</ArticleId><ArticleId IdType="pubmed">37008741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sempé  L, Lloyd-Sherlock  P, Martínez  R, Ebrahim  S, McKee  M, Acosta  E. Estimation of all-cause excess mortality by age-specific mortality patterns for countries with incomplete vital statistics: a population-based study of the case of Peru during the first wave of the COVID-19 pandemic. Lancet Reg Health Am  2021; 2:None.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8507430</ArticleId><ArticleId IdType="pubmed">34693394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes  B, Rodrigues  AP, Kislaya  I, et al.  mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill  2021; 26:2100833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462036</ArticleId><ArticleId IdType="pubmed">34558406</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos  CVBD, Valiati  NCM, Noronha  TG, et al.  The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. Lancet Reg Health Am  2023; 20:100465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10010656</ArticleId><ArticleId IdType="pubmed">36936517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva  T, Andrews  JR, Boaventura  VS, et al.  Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis  2022; 22:791–801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8971277</ArticleId><ArticleId IdType="pubmed">35366959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva  T, de Araujo Oliveira  V, Paixão  ES, et al.  Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nat Commun  2022; 13:4154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289933</ArticleId><ArticleId IdType="pubmed">35851597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani  OT, Hitchings  MDT, de Melo  RL, et al.  Effectiveness of an inactivated COVID-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun  2022; 13:5536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537178</ArticleId><ArticleId IdType="pubmed">36202800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani  OT, Hitchings  MDT, Dorion  M, et al.  Effectiveness of the CoronaVac vaccine in older adults during a Gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. BMJ  2021; 374:n2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377801</ArticleId><ArticleId IdType="pubmed">34417194</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni  C, May  A, Polidori  L, et al.  COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study. Lancet Infect Dis  2022; 22:1002–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara  A, Undurraga  EA, Zubizarreta  JR, et al.  Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health  2022; 10:e798–806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034854</ArticleId><ArticleId IdType="pubmed">35472300</ArticleId></ArticleIdList></Reference><Reference><Citation>
United Nations Department of Economic and Social Affairs, Population Division. World population prospects 2022, online edition. 2022. Available at: https://population.un.org/wpp/Download/Standard/Population/. Accessed March 9, 2023.</Citation></Reference><Reference><Citation>Watson  OJ, Barnsley  G, Toor  J, Hogan  AB, Winskill  P, Ghani  AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis  2022; 22:1293–302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira  LS, Darcie Marquitti  FM, Paixão da Silva  RL, et al.  Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis. Lancet Reg Health Am  2023; 17:100397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9676113</ArticleId><ArticleId IdType="pubmed">36439909</ArticleId></ArticleIdList></Reference><Reference><Citation>Meslé  MM, Brown  J, Mook  P, et al.  Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European region, December 2020 to November 2021. Euro Surveill  2021; 26:2101021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8619871</ArticleId><ArticleId IdType="pubmed">34823641</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Forecasting Team . Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet  2023; 401:833–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda  M, Murata  F, Fukuda  H. Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Int J Infect Dis  2023; 134:200–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10289267</ArticleId><ArticleId IdType="pubmed">37356650</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>